-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 is an extremely extraordinary year, with the gradual deepening of medical reform and the continuous deepening of centralized procurement, which promotes the transformation and upgrading of the pharmaceutical industry
.
The curtain of the pharmaceutical market in 2022 is about to be unveiled.
Let us look back at the 2021 pharmaceutical market's vicissitudes
.
In the context of rapid economic development, the pharmaceutical market has fully recovered
.
China's pharmaceutical economy has restarted growth, the upstream pharmaceutical industry has been operating steadily, and the downstream terminal businesses have undergone fission and integration
.
China's drug sales have gradually differentiated into two major categories of terminal formats, online and offline
.
Offline terminals include hospitals, physical pharmacies and primary medical institutions, and online terminals include platform e-commerce, vertical e-commerce and Internet hospitals and other new retail channel formats
.
The rapid changes in sales terminals have gradually changed the traditional business philosophy
.
Looking to the future, at the beginning of the "14th Five-Year Plan" period, the steady growth of China's pharmaceutical industry embarks on a new journey
.
In the first half of the year, sales of the three major terminals increased by 8.
8%.
According to the "Statistical Bulletin of China's Health Care Development in 2020" published by the National Health Commission in July 2021, among the total number of visits to hospitals in China in 2020, there were 3.
32 billion visits, a year-on-year increase.
A year-on-year decrease of 13.
54%, of which public hospitals accounted for 36% of visits
.
The primary medical and health institutions reached 4.
12 billion person-times, accounting for 53.
2%
.
It can be seen that medical resources are rationally diverted under the guidance of policies
.
With the gradual improvement of the domestic epidemic situation, the number of terminal visits in hospitals will rebound significantly in 2021
.
According to the theme report of the "China Medical and Health Industry Symbiosis Conference", in the first quarter of 2021, the total number of visits to medical and health institutions across the country reached 1.
5 billion, a year-on-year growth rate of 40.
8%, which directly drove the growth of the drug market in public hospitals in key provinces and cities by more than 20%
.
According to data from Minai.
com, in the first half of 2021, the amount of drugs used in China's three major terminals and six major markets reached 839.
3 billion yuan, an increase of 8.
8% over the same period last year
.
From the perspective of the sales distribution of the three major terminals for drug sales, public hospitals have the largest market share, accounting for 63.
80%
.
With the effective control of the domestic epidemic, public medical institutions and retail pharmaceutical terminals have bottomed out and rebounded in the first quarter of 2021, pushing the domestic pharmaceutical market to fully recover
.
According to data from Meinenet, in the first three quarters of 2021, public hospitals in key provinces and cities in China used more than 170 billion yuan of drugs, an increase of 12.
18% over the same period of the previous year
.
It is predicted that in 2021, the amount of drugs used in public hospitals in key provinces and cities in China will exceed 225 billion yuan
.
In the past two years, new policies such as priority review and approval and national talks on price reduction have opened up new horizons for the pharmaceutical market
.
As of mid-December 2021, the National Medical Products Administration (NMPA) has approved 1,144 production approvals for chemical and biological drugs, an increase of 20.
30% from the 926 for the whole year of 2020
.
In the same period, NMPA approved 115 import approval documents, which was a decrease of 23.
33% compared with 150 in the previous year
.
Under the new policies such as drug consistency evaluation, national talks, and volume procurement, the proportion of generic drug sales in the overall drug market has decreased year by year, and the growth rate has slowed sharply.
Innovative drugs have become an important engine for the development of the pharmaceutical industry
.
The domestic market is expected to exceed 2.
66 trillion yuan.
Public data shows that in 2020, the global pharmaceutical product market will reach 1.
39 trillion U.
S.
dollars, and it is predicted to reach 1.
45 trillion U.
S.
dollars in 2021, an increase of 4.
32% from the previous year
.
In recent years, China's pharmaceutical market has been in an incremental period.
Driven by new drugs and targeted drugs, the pharmaceutical manufacturing industry's revenue growth in 2021 is expected
.
It is expected to exceed 2.
66 trillion yuan in 2021, with a year-on-year growth rate of approximately 8.
2%
.
The number of "blockbusters" will exceed 30.
In China, drugs with sales exceeding 1 billion yuan are called heavyweight varieties or blockbuster drugs
.
According to data from Minai.
com, in the first three quarters of 2021, 22 types of drugs in public hospitals in key provinces and cities in China exceeded 1 billion yuan, accounting for nearly 20% of the overall market.
.
Its total sales exceeded 32 billion yuan, an increase of 15.
04% over the previous year
.
From the first quarter to third quarter of 2021, among the heavyweight products that have used medicines in public hospitals in key provinces and cities to exceed 1 billion yuan, oxaliplatin, leuprolide, recombinant human thrombopoietin, pemetrexed, etc.
have been newly added4 New drugs, but butylphthalide and rabeprazole are temporarily withdrawn
.
From 18 drugs in the same period last year to 22 drugs now
.
It is predicted that in 2021, the total number of heavyweight drugs with a total value of 1 billion yuan in public hospitals in key provinces and cities will reach 32
.
The drugs expected to enter this rank in the fourth quarter are: doxorubicin, budesonide, rabeprazole, compound amino acid (18AA), butylphthalide, enteral nutrition, rivaroxaban, ilaprazole , Dexmedetomidine and docetaxel
.
Anti-tumor drugs account for 10 seats.
According to the data of Menet.
com, in the first three quarters of 2021, among the heavyweight drugs in public hospitals in key provinces and cities in China, there are 10 anti-tumor and immunomodulator drugs, namely: bevacizumab and triturate Tocilizumab, rituximab, paclitaxel, osimertinib, oxaliplatin, pemetrexed, leuprolide, tacrolimus and pegylated human granulocyte stimulating factor (thiopeptide Filgrastim)
.
The sales of these 10 drugs reached 13.
5 billion yuan, an increase of 16.
60% over the same period last year
.
Resuscitation of blood and hematopoietic system drugs Blood and hematopoietic system drugs are the main category in the pharmaceutical market
.
According to data from Minai.
com, among the heavyweight drugs in public hospitals in key provinces and cities in China in the first quarter of 2021, there are 4 drugs for blood and hematopoietic system, namely: human albumin, sodium chloride, low molecular heparin and recombinant human platelets Geneogen, its market size exceeds 8 billion yuan, an increase of 13.
76% from the first quarter of 2020, showing obvious signs of recovery
.
.
The curtain of the pharmaceutical market in 2022 is about to be unveiled.
Let us look back at the 2021 pharmaceutical market's vicissitudes
.
In the context of rapid economic development, the pharmaceutical market has fully recovered
.
China's pharmaceutical economy has restarted growth, the upstream pharmaceutical industry has been operating steadily, and the downstream terminal businesses have undergone fission and integration
.
China's drug sales have gradually differentiated into two major categories of terminal formats, online and offline
.
Offline terminals include hospitals, physical pharmacies and primary medical institutions, and online terminals include platform e-commerce, vertical e-commerce and Internet hospitals and other new retail channel formats
.
The rapid changes in sales terminals have gradually changed the traditional business philosophy
.
Looking to the future, at the beginning of the "14th Five-Year Plan" period, the steady growth of China's pharmaceutical industry embarks on a new journey
.
In the first half of the year, sales of the three major terminals increased by 8.
8%.
According to the "Statistical Bulletin of China's Health Care Development in 2020" published by the National Health Commission in July 2021, among the total number of visits to hospitals in China in 2020, there were 3.
32 billion visits, a year-on-year increase.
A year-on-year decrease of 13.
54%, of which public hospitals accounted for 36% of visits
.
The primary medical and health institutions reached 4.
12 billion person-times, accounting for 53.
2%
.
It can be seen that medical resources are rationally diverted under the guidance of policies
.
With the gradual improvement of the domestic epidemic situation, the number of terminal visits in hospitals will rebound significantly in 2021
.
According to the theme report of the "China Medical and Health Industry Symbiosis Conference", in the first quarter of 2021, the total number of visits to medical and health institutions across the country reached 1.
5 billion, a year-on-year growth rate of 40.
8%, which directly drove the growth of the drug market in public hospitals in key provinces and cities by more than 20%
.
According to data from Minai.
com, in the first half of 2021, the amount of drugs used in China's three major terminals and six major markets reached 839.
3 billion yuan, an increase of 8.
8% over the same period last year
.
From the perspective of the sales distribution of the three major terminals for drug sales, public hospitals have the largest market share, accounting for 63.
80%
.
With the effective control of the domestic epidemic, public medical institutions and retail pharmaceutical terminals have bottomed out and rebounded in the first quarter of 2021, pushing the domestic pharmaceutical market to fully recover
.
According to data from Meinenet, in the first three quarters of 2021, public hospitals in key provinces and cities in China used more than 170 billion yuan of drugs, an increase of 12.
18% over the same period of the previous year
.
It is predicted that in 2021, the amount of drugs used in public hospitals in key provinces and cities in China will exceed 225 billion yuan
.
In the past two years, new policies such as priority review and approval and national talks on price reduction have opened up new horizons for the pharmaceutical market
.
As of mid-December 2021, the National Medical Products Administration (NMPA) has approved 1,144 production approvals for chemical and biological drugs, an increase of 20.
30% from the 926 for the whole year of 2020
.
In the same period, NMPA approved 115 import approval documents, which was a decrease of 23.
33% compared with 150 in the previous year
.
Under the new policies such as drug consistency evaluation, national talks, and volume procurement, the proportion of generic drug sales in the overall drug market has decreased year by year, and the growth rate has slowed sharply.
Innovative drugs have become an important engine for the development of the pharmaceutical industry
.
The domestic market is expected to exceed 2.
66 trillion yuan.
Public data shows that in 2020, the global pharmaceutical product market will reach 1.
39 trillion U.
S.
dollars, and it is predicted to reach 1.
45 trillion U.
S.
dollars in 2021, an increase of 4.
32% from the previous year
.
In recent years, China's pharmaceutical market has been in an incremental period.
Driven by new drugs and targeted drugs, the pharmaceutical manufacturing industry's revenue growth in 2021 is expected
.
It is expected to exceed 2.
66 trillion yuan in 2021, with a year-on-year growth rate of approximately 8.
2%
.
The number of "blockbusters" will exceed 30.
In China, drugs with sales exceeding 1 billion yuan are called heavyweight varieties or blockbuster drugs
.
According to data from Minai.
com, in the first three quarters of 2021, 22 types of drugs in public hospitals in key provinces and cities in China exceeded 1 billion yuan, accounting for nearly 20% of the overall market.
.
Its total sales exceeded 32 billion yuan, an increase of 15.
04% over the previous year
.
From the first quarter to third quarter of 2021, among the heavyweight products that have used medicines in public hospitals in key provinces and cities to exceed 1 billion yuan, oxaliplatin, leuprolide, recombinant human thrombopoietin, pemetrexed, etc.
have been newly added4 New drugs, but butylphthalide and rabeprazole are temporarily withdrawn
.
From 18 drugs in the same period last year to 22 drugs now
.
It is predicted that in 2021, the total number of heavyweight drugs with a total value of 1 billion yuan in public hospitals in key provinces and cities will reach 32
.
The drugs expected to enter this rank in the fourth quarter are: doxorubicin, budesonide, rabeprazole, compound amino acid (18AA), butylphthalide, enteral nutrition, rivaroxaban, ilaprazole , Dexmedetomidine and docetaxel
.
Anti-tumor drugs account for 10 seats.
According to the data of Menet.
com, in the first three quarters of 2021, among the heavyweight drugs in public hospitals in key provinces and cities in China, there are 10 anti-tumor and immunomodulator drugs, namely: bevacizumab and triturate Tocilizumab, rituximab, paclitaxel, osimertinib, oxaliplatin, pemetrexed, leuprolide, tacrolimus and pegylated human granulocyte stimulating factor (thiopeptide Filgrastim)
.
The sales of these 10 drugs reached 13.
5 billion yuan, an increase of 16.
60% over the same period last year
.
Resuscitation of blood and hematopoietic system drugs Blood and hematopoietic system drugs are the main category in the pharmaceutical market
.
According to data from Minai.
com, among the heavyweight drugs in public hospitals in key provinces and cities in China in the first quarter of 2021, there are 4 drugs for blood and hematopoietic system, namely: human albumin, sodium chloride, low molecular heparin and recombinant human platelets Geneogen, its market size exceeds 8 billion yuan, an increase of 13.
76% from the first quarter of 2020, showing obvious signs of recovery
.